In this case, the goal of the inhibitor design is to target S100B, but avoid other S100s such as S100A1, which are important for other important biological functions, such as cardiac and skeletal muscle function.198 Thus, a complete understanding of allosteric CBP-target interactions that are specific for one versus another S100 protein will significantly facilitate this goal and are ongoing to advance the engineering of S100-specific inhibitors for cancer as well as other disease states. The gene discussed is S100A1; the disease is cancer.